E

Z

X

S

Saving Pets Lives. 
Improving Pet Owners  Lifestyles

by Koglo Ltd.

Chronic Kidney Disease in Pets

In general, Chronic Kidney Disease (sometimes called kidney failure) happens when your pets' kidneys stop doing their job as well as they should. Chronic Kidney Disease (CKD) is one of the most commonly
diagnosed diseases in pets. In most cases, CKD is a progressive disease and can be accompanied by a wide range of clinical ailments.

 

It is the most common
cause of death in cats

Killing 13% of all cats over 5 years old.

1 in 3 cats, and 1 in 10 dogs

will suffer from kidney disease during their lifetime.

5,000,000 pets around the world

are being treated with fluids on a daily-basis, at home, by their owners.

Dramatic increase in diagnosed CKD

Thanks to new tests available on the market, vets are now able to diagnose CKD in earlier stages.

 

Fluid Treatment

When CKD pets suffer from damaged kidneys, which can no longer concentrate urine, they are at risk of dehydration. In early stage CKD, pets can usually drink enough to maintain hydration but eventually most CKD pets will need fluid therapy. The most efficient and common way of fluid therapy, is to administer SQ (under the skin) fluids on a daily basis. SQ fluids are preferably being administered at home, by the pets owner, using an exposed needle and a standard fluids giving set. SQ fluids improves the quality, longevity and disease control.

Usually requires two caretakers

Two hands to restrain the pet, and another two to administer the needle under the skin.

Injury risk due to a
nonprofessional user

As owners (non-vets) administer the needle, there is greater risk of injury due to misuse.

Complex process for untrained caretaker

Pets owners are the caretaker when it comes to fluids  treatment. This is usually the first time they are required  to follow such a procedure.

Needle phobia involving an exposed-needle.

Owners can be horrified by the need to insert a needle to their pets skin on a daily basis

Difficulty in restraining the pet.

It can be complicated to keep your pet calm and restrained through a 10-15 min procedure.

The Problem with Fluid treatment

Like any treatment being administered at home by untrained caretaker, SQ fluids treatment is no different. Using exposed needle and inserting it into your pet's body, could be complex and frightening.

E

Z

X

S

The Solution

An Innovative device for home-use, simplifying the process of fluids-therapy in cats and dogs. The device Provide maximum safety for pets,with minimum stress for the owners and caretakers.

Automated and mechanically guided procedure.

spring driven needle, protected along functional cycle, preventing usage mistakes, with maximal safety. 

The needle is invisible through the whole process.

Eliminating any needle-phobia and anxiety from the user.

Safety mechanism to eliminate injuries

Prevents unintended needle release and fluids dripping.

Improving the restraint in cats.

The device creates natural "Scruffing effect"  that deactivates cats.

Only 1 caretaker is needed.

The device clips on the skin, allowing single-hand activation. Suitable for both right and left handed.

 

Improving Pet Owners Lifestyle

With EZXS pets owners are able to use fluids treatment at home, safely and stress-free

Saving Pets Lives

Presenting the best solution for pets fluids-treatment that dramatically simplifies this procedure. Making this life saving treatment accessible and affordable.

Competitive landscape

Solutions that are currently available for administrating fluids-treatment for pets

Veterinary clinic visits

Safety

 

 

Cost

 

 

Skills needed

 

 

Stress involved

 

 

Commonness

Strength: Performed by professional

Weakness:

Very (very) expensive Requires a daily trip to the clinic. The Opportunity: Providing an easy-to-use solution, that allows an untrained caretaker to perform the procedure like a professional, at home.

Standard giving-set at home

Safety

 

 

Cost

 

 

Skills needed

 

 

Stress involved

 

 

Commonness

Strength: Cost-effective

Weakness:

Needle-phobia involving an exposed needle. Difficulty restraining the pet. Potential injury due to nonprofessional user. Usually requires two caretakers. Complex process for untrained caretaker. The Opportunity: Providing a stress free solution for an affordable price.

EZXS

Safety

 

 

Cost

 

 

Skills needed

 

 

Stress involved

Safest solution
Affordable price
Minimal skills required
Improving ability to restraint
Stress free for both the pet and the owner

Unique Features

Designed especially to assist untrained caretakers, creating a perfect fit for the needs of the market.

Market Penetration

Projecting a relatively quick market penetration since EZXS will be introduced and sold by vets that are searching for such a solution.

Safety

Fully automated and mechanically guided procedure, enabling the safest solution around.

First to Market

The first and only solution that simplify this common and complicated procedure.

Unique Pricing Model

EZXS includes a reusable competent and a disposable component (needle cartridge). enabling a seamless introduction to new users while generating profits for several years.

Proprietary Technology

EZXS is protected by filed patents. US Provisional Patent Application No. 62/746,021

Competitive landscape

Solutions that are currently available for administrating fluids-treatment for pets

 

Revenue Model

EZXS Will be sold to distributors for $25-$30 per 30-days kit, reflecting profitability of 80%-100%. The price for the end-user (pet owner) will be 70$-100$.

Yearly-revenue projection based on:

1% market penetration = $18 million 2.5% market penetration = $45 million  5% market penetration = $90 million  10% market penetration = $180 million

Alpha prototype production.
Feasibility test.
Testing the prototype on live cats.
Feasibility tests conclusions application.  Improving and finalizing EZXS.
Pre-launch marketing and business development.
Finding the right distributors and business collaborations.
Design for manufacture.
Manufacture and Distribution.
Increase marketing efforts and sales.

Achieved

Market research.
Including in-depth interview with vets from US, Europe and Israel.
Established Koglo ltd.
Initial start-up funds were self-invested, in order to set the company's legal foundations.
Team finalized.

Veterinary, business, engineer and product design.
Concept development.
Based on market needs, target price, manufacturing costs, veterinarian feedback , etc.
Patent application submitted.
Provisional, in US, through a top-tier legal firm.
Prototype development and design plans. Ready for production with an Alpha 3D prototype.

In the next 12 months 

 Alpha prototype production.
Feasibility test.
Testing the prototype on live cats.
Feasibility tests conclusions application. 
Improving and finalizing EZXS.
Pre-launch marketing and business development.
Finding the right distributors and business collaborations.
Design for manufacture.
Manufacture and Distribution.
Increase marketing efforts and sales.

Milestones

The Team

  • Yotam Kaufman

    Founder and Chief Executive Officer

    Offline and Online marketing expert with experience expanding to US and EU. Experience from large global companies.

  • Gilad Lavi

    VP R&D

    Mechanical engineer with extensive experience in R&D of medical devices, specializing in drug delivery technologies. Over 30 years of experience, leading bio - medical companies and development teams.

  • Prof. Gilad Segev

    Lead veterinary consultant

    Head department, Small Animal Internal Medicine Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food & Environment, The Hebrew University 

    of Jerusalem.International Renal Interest Society award winner (2009). Board member, the International Renal Interest Society.

  • Dr. Shlomo Amiel

    Medical Director

    Veterinary surgeon, managing 

    a private clinic. Veterinary physician of The Oketz Unit, (the independent canine Special Forces unit of the Israel Defense Forces). Business development consultant for pet-med companies.

 
 

The Ask

Funding Goals

After a successful initial development stage and POC, we strive to introduce EZXS to the market. The funds will be used for:
Alpha prototype production.
Feasibility test.
Product improvements based on the feasibility tests conclusions. Pre-launch marketing and business development.
Design for manufacture.
Manufacturing and distribtion. 
Increase marketing and sales.

Timeline

Ready to manufacture in 6 months. Launch in 9 months.
Start generating revenue in 
12 months.

Funding Allocations

$2,500,000

22% Salaries
35% Production
8% Legal
12% Marketing
23% R&D

 

Let’s do it together!

EZXS

Saving Pets Lives. 
Improving Pet Owners 
Lifestyles

by Koglo Ltd.